{‘She has no experience’: the American scientific field girds for Dr. Høeg's tenure at the Food and Drug Administration.

As America proceeds with unprecedented changes to its immunization recommendations, an unexpected name appears unexpectedly: Høeg, an American of Danish descent physician and public health researcher who initially gained attention by questioning COVID-19 vaccines during the pandemic and has zeroed in on potential deaths after Covid vaccination in her short time at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Vaccine Program

Agency leaders were set to reveal sweeping changes to the childhood immunization program recently, synchronizing the US with the Danish immunization schedule, sources say – a significant shift that would place the US out of step with much of the global community with little proof for benefit. The planned update has been delayed until the coming year.

Instead of the director of the vaccine center, Dr. Høeg is set to present at the meeting. She was just designated acting director of the FDA’s CDER, the fifth appointee to head the division this year.

A Shift at the FDA

This interim role might represent a tighter collaboration between the drug and vaccine centers as Høeg and Prasad consolidate power at the FDA – and it suggests a renewed priority upon dismantling long-standing immunizations at the FDA.

Høeg has frequently advocated for discontinuing certain childhood vaccine recommendations in the US in order to be more like Denmark's approach, a country with comprehensive healthcare and a citizenry about the population of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccination policy – traditionally the purview of Dr. Prasad, head of the FDA’s CBER – rather than medication approval.

Concerns Over Background

The appointee has no obvious background in medication creation, oversight or leadership, which has been standard for past heads of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, stated Jonathan Howard. “She has not conducted a randomized controlled trial. She has no expertise in managing a major agency. She is not an expert in industry regulation.”

Past directors of the center would “understand regulatory frameworks and the science of drug development”, said Janet Woodcock. “Frankly, she has not acquired the sort of resume that former directors who ran CBER have had.”

CDER has an immense range of responsibilities at the FDA, she pointed out.

“Everybody just zeroes in on the new drug program, but the generic program approves a multitude of generic medications. There’s a biosimilars division, non-prescription drug unit and more, and all of those have to be managed,” Woodcock noted. “The area you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Furthermore, a major leadership component to the role, which oversees over 5,000 employees. “It’s a massive leadership role, if you perform it correctly,” Woodcock concluded.

Official Statement and Contentious Policies

Regarding inquiries about Høeg’s credentials and whether this appointment signifies increased cooperation among agency officials on immunizations, a representative said that the “inquiries stem from flawed presumptions”.

“Her experience aligns with the responsibilities of her job,” the official explained, citing the time Høeg spent counseling the FDA commissioner on “drug safety and approval science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg inherits the agency head's controversial priority voucher program, a contentious one-day therapy clearance system that reportedly troubled her former heads. “By what process are these drugs being chosen for this expedited pathway? Who makes the calls?” Howard asked. “There’s a lot of confidentiality happening at the FDA right now.”

In general, he remarked, “the FDA looks to be trending towards more relaxed regulations of pharmaceuticals, except for vaccines.”

Public Past Work on Vaccines

With immunizations, Dr. Høeg has a more documented, if troubling, past, some experts observe. She published a analysis using unverified public submissions to assess the incidence of myocarditis after COVID-19 vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who allegedly have modified findings to indicate COVID-19 vaccines are more dangerous than they are.

Among her “wish list” for the current federal leadership featured altering rules for novel immunizations and discontinuing “unnecessary” vaccines, she stated after the election on a audio program. At the agency, Dr. Høeg has according to sources suggested preventing teenage boys from receiving COVID-19 vaccinations.

“She’s an complete true believer who starts off with her beliefs and reverse-engineers to retrofit the data in a extremely disingenuous, fraudulent way,” Howard argued.

Consolidating Power and a “Revenge Tour”

Dr. Høeg became part of other dissenters, {like|